Agreement of the Joint Committee on Vaccination and Immunisation on the pneumococcal vaccination; Difficulties in the introduction of the vaccine; Benefits of the vaccine. INSETS: The annual burden of disease ...
FDA approval on February 24 was based on data from a study (n = 7844) showing that the new 13-valent vaccine elicited immune responses comparable to that achieved with the 7-valent PCV. Both vaccines are administered on a 4-dose schedule administered at ages 2, 4, and 6 months and ages...
Children with asthma are at much greater risk for invasive pneumococcal disease (IPD), even if they have received the pneumococcal conjugate vaccine (PCV), a systematic review and meta-analysis have found. Jose A. Castro-Rodriguez, MD, PhD, from the Pontificia Universidad Católica de Chile, ...
This study was performed to estimate the effect of heptavalent pneumococcal conjugate vaccine (PCV7) on the pneumonia admission rate in children younger than 5years of age, after the introduction of routine 2+1 dose schedule immunization. We compared the pneumonia admission rate (number of cases ...
The 13-valent pneumococcal conjugate vaccine (PCV) has been part of routine immunisation in a 2 + 1 schedule (two primary infant doses and one booster during the second year of life) in the UK since 2010. Recently, the UK's Joint Committee on Vaccination and Immunisation recommended changing...
A single PCV7 dose at age 12 months in previously unvaccinated subjects (“catch up” schedule) resulted in poor SSIgG concentrations for three out of seven serotypes, resulting in higher acquisition and prevalence rates of vaccine serotypes (grouped) compared to infants receiving a booster dose...
Immunogenicity of a Reduced Schedule of Meningococcal Group C Conjugate Vaccine Given Concomitantly with the Prevenar and Pediacel Vaccines in Healthy Infa... This study investigated the use of two doses of three different meningococcal group C conjugate (MCC) vaccines when given for primary immuniza...
Conclusions: HCPs and caregivers were virtually unanimous in their support for a PCV with broader serotype coverage and showed a subsequent willingness to include an extra infant dose/visit. These results can help guide broader discussions regarding public health policy and vaccine administration in the...
Combined schedule of 7-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal vaccine in children and young adults with sickle cell disease. J Pediatr. 1998 Aug;133(2):275-8.Vernacchio L, Neufeld EJ, MacDonald K, Kurth S, Murakami S, Hohne C, et al. Combined schedule of...
Combined schedule of 7-valent pneumococcal conju- gate vaccine followed by 23-valent pneumococcal vaccine in children and young adults with sickle cell disease. J Pediatr. 1998; 103:275-8.Vernacchio L, Neufeld EJ, MacDonald K, Kurth S, Mu- rakami S, Hohne C, King M, Molrine D. ...